Full Title
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer: APOLLOPurpose
Researchers want to find the best dose of AZD0754 for people with prostate cancer. The patients in this study have prostate cancer that has metastasized (spread).
AZD0754 is a form of treatment called CAR T-cell therapy, which is made of specialized white blood cells. If you take part in this study, we will collect some of your T cells. We will modify (change) them in a lab to make AZD0754.
You will have a very short course of chemotherapy to reduce the cells that can interfere with the effectiveness of the modified T cells. Then you will have one dose of AZD0754. This treatment is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have metastatic castration-resistant prostate cancer (cancer that keeps growing in the absence of testosterone).
- Have recovered from the serious side effects of prior therapies before getting AZD0754.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Susan Slovin’s office at 646-422-4470.